BS_M8M56Z4Y
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 56.53745072273324
- age_years
- 11.197
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.382
- INTERFERON_GAMMA_RESPONSE+0.344
- NOTCH_SIGNALING+0.319
- COAGULATION+0.313
- MYOGENESIS+0.309
- INFLAMMATORY_RESPONSE+0.293
- IL6_JAK_STAT3_SIGNALING+0.274
- KRAS_SIGNALING_DN+0.274
- XENOBIOTIC_METABOLISM+0.269
- ALLOGRAFT_REJECTION+0.268
Top 10 suppressed
- G2M_CHECKPOINT-0.545
- E2F_TARGETS-0.525
- MYC_TARGETS_V1-0.525
- MITOTIC_SPINDLE-0.381
- PROTEIN_SECRETION-0.340
- ANDROGEN_RESPONSE-0.335
- UNFOLDED_PROTEIN_RESPONSE-0.321
- MTORC1_SIGNALING-0.293
- SPERMATOGENESIS-0.215
- ANGIOGENESIS-0.153
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QTSXW7DA | pilocytic astrocytoma | — | 0.882 |
| 2 | R46 | — | — | 0.880 |
| 3 | SAMN03290921 | — | — | 0.880 |
| 4 | BS_4BWB0FA0 | low-grade glioma | — | 0.870 |
| 5 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.865 |
| 6 | BS_EYSS0ZDS | low-grade glioma | — | 0.864 |
| 7 | SAMN03290902 | — | — | 0.863 |
| 8 | SAMN03290904 | — | — | 0.861 |
| 9 | 002260fb-3015-4876-b8fd-edffd7fc95e8 | — | — | 0.860 |
| 10 | TCGA-AR-A5QM-01A-11R-A27Q-07 | — | A | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.382 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.344 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.319 | Inavolisib | — uncovered |
| COAGULATION | 0.313 | Binimetinib | — uncovered |
| MYOGENESIS | 0.309 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.293 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.274 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.274 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.269 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.268 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.265 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.249 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.202 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.196 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.188 | Inavolisib | — uncovered |
| HYPOXIA | 0.167 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.164 | Idelalisib | — uncovered |
| COMPLEMENT | 0.151 | Inavolisib | — uncovered |